| 1 |
34636352 | BRAF mutations in thyroid cancer. | 2022 Jan 1 |
1 |
| 2 |
35038965 | Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies. | 2022 Apr |
1 |
| 3 |
35045748 | Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. | 2022 Mar |
2 |
| 4 |
35501518 | The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. | 2022 May 2 |
1 |
| 5 |
34234465 | The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF V600E Mutation. | 2021 |
4 |
| 6 |
34595070 | Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib. | 2021 Aug |
1 |
| 7 |
31375570 | The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer. | 2020 Feb |
1 |
| 8 |
31949496 | The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer. | 2020 |
3 |
| 9 |
32575591 | Correlation between F18-FDG PET/CT Imaging and BRAF V600E Genetic Mutation for the Early Assessment of Treatment Response in Papillary Thyroid Cancers. | 2020 Jun 19 |
1 |
| 10 |
30256977 | Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. | 2019 May 1 |
1 |
| 11 |
30312216 | The BRAFV600E mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy? | 2019 Jan |
1 |
| 12 |
30396219 | BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer. | 2019 Jan |
2 |
| 13 |
31412230 | MOLECULAR PROFILE AND CLINICAL OUTCOMES IN DIFFERENTIATED THYROID CANCER PATIENTS PRESENTING WITH BONE METASTASIS. | 2019 Dec |
1 |
| 14 |
29567362 | BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy? | 2018 May |
3 |
| 15 |
29651624 | In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related. | 2018 May |
2 |
| 16 |
29762246 | BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases. | 2018 Jul |
1 |
| 17 |
30337961 | Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells. | 2018 |
2 |
| 18 |
30541319 | The Significance of BRAFV600E Mutation in Thyroid Cancer in Terms of Novel Targeted Therapies - Overview of Current Knowledge and Studies. | Fall 2018 |
1 |
| 19 |
27493271 | TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer. | 2017 Feb |
1 |
| 20 |
28423638 | HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E. | 2017 Mar 21 |
2 |
| 21 |
29264486 | Restoring Radioiodine Uptake in BRAF V600E-Mutated Papillary Thyroid Cancer. | 2017 Apr 1 |
3 |
| 22 |
26751190 | Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells. | 2016 Mar |
1 |
| 23 |
26838744 | Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma. | 2016 Feb |
1 |
| 24 |
26857243 | Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. | 2016 Feb 9 |
2 |
| 25 |
27544995 | Clinical Outcome of Radioiodine Therapy in Low-intermediate Risk Papillary Thyroid Carcinoma with BRAF(V600E) Mutation. | 2016 Jun 10 |
2 |
| 26 |
25549723 | Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. | 2015 Mar 1 |
2 |
| 27 |
23845288 | BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity. | 2014 Feb |
1 |
| 28 |
24243688 | Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. | 2014 Apr |
2 |
| 29 |
24955023 | Molecular pathways associated with aggressiveness of papillary thyroid cancer. | 2014 Jun |
1 |
| 30 |
23066120 | The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. | 2012 Dec |
1 |
| 31 |
23163107 | Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas. | 2012 |
1 |
| 32 |
22105174 | Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. | 2011 Dec |
4 |
| 33 |
19883729 | Prognostic utility of BRAF mutation in papillary thyroid cancer. | 2010 May 28 |
3 |
| 34 |
21134544 | BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. | 2010 Dec |
1 |
| 35 |
19169486 | Seven-year follow-up of a juvenile female with papillary thyroid carcinoma with poor outcome, BRAF mutation and loss of expression of iodine-metabolizing genes. | 2008 Nov |
2 |
| 36 |
17317846 | Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. | 2007 Feb 15 |
2 |
| 37 |
17488796 | BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. | 2007 Jul |
1 |